NL-OMON30076尚未招募2 期
A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Exploratory Study of the Safety and Efficacy of Oral R115866 vs. R115866 Placebo in the Treatment of Plaque Psoriasis - Oral R115866 psoriasis dose ranging study
Synergie/ Ilse pharma consultancy0 个研究点目标入组 37 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Subject must be 18 years of older. Subject should be male or female not of childbearing potential. Subject should have a clinical diagnose of plaque psoriasis with a BSA of more then 10% and a PASI of more then 10.
排除标准
- •Subject has a history of sensitivity to any of the ingredients in the study medication
- •Subject is currently participating in, or has within the 30 days prior to the clinical trial participated in an investigational clinical trial.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Exploratory Study of the Safety and Efficacy of Oral R115866 vs. R115866 Placebo in the Treatment of Plaque Psoriasis - Oral R115866 psoriasis dose ranging studyTreatment of Plaque PsoriasisEUCTR2005-004623-19-IEBarrier Therapeutics, Inc.192
进行中（未招募）
1 期
A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Exploratory Study of the Safety and Efficacy of Oral R115866 vs. R115866 Placebo in the Treatment of Plaque Psoriasis - Oral R115866 psoriasis dose ranging studyTreatment of Plaque PsoriasisEUCTR2005-004623-19-GBBarrier Therapeutics, Inc.
进行中（未招募）
不适用
A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Exploratory Study of the Safety and Efficacy of Oral R115866 vs. R115866 Placebo in the Treatment of Plaque Psoriasis - Oral R115866 psoriasis dose ranging studyTreatment of Plaque PsoriasisEUCTR2005-004623-19-NLBarrier Therapeutics, Inc.192
进行中（未招募）
1 期
A Study to Assess Safety, Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy AdultsEbolaMedDRA version: 20.0 Level: PT Classification code 10014071 Term: Ebola disease System Organ Class: 10021881 - Infections and infestationsEUCTR2015-000596-27-GBJanssen Vaccines & Prevention BV421
终止
1 期
A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of a novel Receptor Binding Domain (RBD) COVID-19 Vaccine in Healthy AdultsSARS-CoV-2COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620001308987Accelagen Pty Ltd35